Altogether, these studies demonstrate that stimulation of the antiviral innate immune response before infection or at the very early stage of infection inhibits SARS-CoV-2 replication and pathogenesis, as expected given the high level of SARS-CoV-2 sensitivity to prophylactic type I and type III IFN treatment observed in cell culture [2–4]. This evidence concerns the gene IFNA1 and infection.